Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy

Part of paid clinical trials in Dallas, Texas.

Sponsor
Akouos, Inc.
Study ID
NCT07503613
Status
Enrolling By Invitation

Conditions

  • Vestibular Schwannoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

This multi-center, observational, post-intervention LTFU study will monitor for safety and efficacy of AAVAnc80- antiVEGF in individuals with vestibular schwannoma who have previously received an intracochlear administration of AAVAnc80-antiVEGF in an interventional clinical trial

Key Dates

Start date
Mar 2, 2026
Status verified
Mar 2026
Primary completion
Apr 30, 2040
Completion
Apr 30, 2040

Study Design

Enrollment
100 participants (estimated)

Arms

  • Arm: Study Participants
    Individuals with vestibular schwannoma who received an intracochlear administration of AAVAnc80-antiVEGF in an interventional clinical trial.

Primary Outcome Measure

Long term safety of AAVAnc80-antiVEGF, including late-occurring adverse events (AEs [ Time Frame: Through study completion, approximately four years. ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Texas SouthwesternDallasTexas75390-

Find similar trials in Dallas, TX

By research site
University of Texas Southwestern· Dallas, TX

Related Studies